Vertex Pharmaceuticals Return on Equity

Vertex Pharmaceuticals (VRTX) currently reports a ROE of 21.76%. That is above the Healthcare sector average of 20.86%. Use the charts on this page to explore Vertex Pharmaceuticals's ROE history and peer comparisons.

Vertex Pharmaceuticals's ROE of 21.76% is higher than the Healthcare sector average of 20.86%. That is roughly 4.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Vertex Pharmaceuticals's current 21.76% should be judged against Healthcare norms (sector average: 20.86%) and against VRTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 21.76%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Vertex Pharmaceuticals, and consider following VRTX for alerts when major investors trade the stock.

Vertex Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 21.76% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VRTX with unrelated industries.